National Institutes of Health/Office of the Director
OD021345
米国
National Institutes of Health/Eunice Kennedy Shriver National Institute of Child Health & Human Development (NIH/NICHD)
HD101596
米国
National Institutes of Health/National Cancer Institute (NIH/NCI)
CA260415
米国
The Vallee Foundation Inc.
米国
Richard and Susan Smith Family Foundation
米国
National Institutes of Health/National Institute of Neurological Disorders and Stroke (NIH/NINDS)
NS088566
米国
The Pew Charitable Trusts
米国
引用
ジャーナル: Nat Chem Biol / 年: 2024 タイトル: Antibodies expand the scope of angiotensin receptor pharmacology. 著者: Meredith A Skiba / Sarah M Sterling / Shaun Rawson / Shuhao Zhang / Huixin Xu / Haoran Jiang / Genevieve R Nemeth / Morgan S A Gilman / Joseph D Hurley / Pengxiang Shen / Dean P Staus / Jihee ...著者: Meredith A Skiba / Sarah M Sterling / Shaun Rawson / Shuhao Zhang / Huixin Xu / Haoran Jiang / Genevieve R Nemeth / Morgan S A Gilman / Joseph D Hurley / Pengxiang Shen / Dean P Staus / Jihee Kim / Conor McMahon / Maria K Lehtinen / Howard A Rockman / Patrick Barth / Laura M Wingler / Andrew C Kruse / 要旨: G-protein-coupled receptors (GPCRs) are key regulators of human physiology and are the targets of many small-molecule research compounds and therapeutic drugs. While most of these ligands bind to ...G-protein-coupled receptors (GPCRs) are key regulators of human physiology and are the targets of many small-molecule research compounds and therapeutic drugs. While most of these ligands bind to their target GPCR with high affinity, selectivity is often limited at the receptor, tissue and cellular levels. Antibodies have the potential to address these limitations but their properties as GPCR ligands remain poorly characterized. Here, using protein engineering, pharmacological assays and structural studies, we develop maternally selective heavy-chain-only antibody ('nanobody') antagonists against the angiotensin II type I receptor and uncover the unusual molecular basis of their receptor antagonism. We further show that our nanobodies can simultaneously bind to angiotensin II type I receptor with specific small-molecule antagonists and demonstrate that ligand selectivity can be readily tuned. Our work illustrates that antibody fragments can exhibit rich and evolvable pharmacology, attesting to their potential as next-generation GPCR modulators.
超分子 #1: AT118-H Nanobody Antagonist in Complex with the Angiotensin II Ty...
超分子
名称: AT118-H Nanobody Antagonist in Complex with the Angiotensin II Type I Receptor BRIL Fusion, Anti-BRIL Fab, and Anti-Fab Nanobody タイプ: complex / ID: 1 / 親要素: 0 / 含まれる分子: #1-#3
由来(天然)
生物種: Homo sapiens (ヒト)
-
分子 #1: AT118-H nanobody, Type-1 angiotensin II receptor, Soluble cytochr...